median age, years (range) | 65 (21-92) |
median ALC, x109/L (range) | 14 (2-460) |
median β2M, xULN (range) | 1.06 (0.13-11.9) |
LNR ≥3 | 25% |
Rai stage | Â |
   0 | 48% |
   I-II | 44% |
   III-IV | 8% |
Binet stage | Â |
   A | 70% |
   B | 22% |
   C | 8% |
Male sex | 60% |
CD38 expression >30% | 27% |
ZAP-70 expression >20% | 41% |
Unmutated IgVH | 41% |
del11q- | 9% |
del17p- | 10% |
Year of diagnosis | Â |
   <=2000 | 29% |
   2001-2005 | 49% |
   >2005 | 22% |
Treated | 53% |
median TTT, years | 5.2 |
   Chemotherapy | 28% |
   Chemoimmunotherapy | 15% |
   missing data | 10% |
Dead | 20% |
median OS, years | 15 |